Business Context and Reporting Period
This Form 8-K is filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) for the reporting period ending March 3, 2025. The filing addresses material definitive agreements, executive leadership changes, and compliance status with Nasdaq listing requirements.
Key Financial Metrics and Liquidity
This filing is a current report regarding corporate governance and listing status; it does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The filing discloses the following new monthly cash compensation obligations:
- CEO Compensation: $12,500 per month (Richard Paolone).
- CFO Compensation: $8,333 per month (Anna Skowron).
- Director Compensation: $2,500 per month per director (5 directors total).
Material Changes and Corporate Actions
Executive Leadership Changes
- Resignation: Sarah Romano resigned as Chief Financial Officer, effective March 7, 2025. The resignation was not due to disagreements regarding operations or financial reporting.
- Appointment: Anna Skowron was appointed Chief Financial Officer, effective March 7, 2025.
- CEO Agreement: Richard Paolone, previously Interim CEO, entered into a formal consulting agreement effective February 12, 2025.
Nasdaq Listing Compliance
- Minimum Bid Price: The Company received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The new deadline is September 1, 2025. Failure to comply may result in delisting.
- Annual Meeting Rule: The Company was granted an extension until June 30, 2025, to hold its annual meeting of shareholders to comply with Nasdaq Listing Rule 5620(a).
- Delisting Risk: There is no assurance the Company will regain compliance with the Minimum Bid Price Requirement by September 1, 2025. If compliance is not met, the stock may be delisted, and any appeal to a hearings panel is not guaranteed to be successful.
- Management Continuity: The Company has secured new executive leadership (CEO and CFO) and formalized director compensation to stabilize governance.
- Compliance Monitoring: Management intends to monitor the stock bid price and may consider options to regain compliance, though specific strategies (e.g., reverse stock split) are not detailed in this filing.
- Verify the current trading price of ENTO to assess the likelihood of meeting the $1.00 bid price requirement by September 1, 2025.
- Confirm the date of the upcoming annual shareholder meeting to ensure it occurs before the June 30, 2025 deadline.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for full terms of the new executive and director compensation agreements.
- Monitor future filings for any announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.